Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone
Authors
Keywords
Metastatic colorectal cancer, 5-fluorouracil, Leucovorin, Chemotherapy
Journal
CANCER TREATMENT REVIEWS
Volume 98, Issue -, Pages 102218
Publisher
Elsevier BV
Online
2021-05-04
DOI
10.1016/j.ctrv.2021.102218
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Folate pathway gene expression in metastatic colorectal cancer patients treated with arfolitixorin/5-FU-based chemotherapy.
- (2021) Roger Tell et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis
- (2020) Luís Nunes et al. ACTA ONCOLOGICA
- Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer
- (2020) Anne Dyhl-Polk et al. ACTA ONCOLOGICA
- AGENT: An open-label phase III study of arfolitixorin versus leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer.
- (2020) Heinz-Josef Lenz et al. JOURNAL OF CLINICAL ONCOLOGY
- TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
- (2020) Per Pfeiffer et al. LANCET ONCOLOGY
- O-19 Feasibility of switching to S-1 upon other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors
- (2020) P. Osterlund et al. ANNALS OF ONCOLOGY
- 464P Pharmacokinetic analysis of NUC-3373 with and without leucovorin in patients with previously treated metastatic colorectal cancer (NuTide:302 study)
- (2020) J. Graham et al. ANNALS OF ONCOLOGY
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- NuTide:302: A phase Ib study to assess the safety, pharmacokinetics and clinical activity of the ProTide NUC-3373 when combined with standard agents used in colorectal cancer.
- (2019) T.R. Jeffry Evans et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment
- (2019) Philip R. Clingan et al. Asia-Pacific Journal of Clinical Oncology
- Consequences of a high incidence of microsatellite instability and BRAF‐ mutated tumors: A population‐based cohort of metastatic colorectal cancer patients
- (2019) Kristine Ø. Aasebø et al. Cancer Medicine
- DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
- (2019) Theodore J. Wigle et al. Pharmaceutics
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
- (2019) Cathy Eng et al. LANCET ONCOLOGY
- Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial
- (2019) Stine Braendegaard Winther et al. Lancet Gastroenterology & Hepatology
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
- (2019) Scott Kopetz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients
- (2019) Xia-Hong You et al. Frontiers in Oncology
- 527PDTrastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial
- (2019) J H Strickler et al. ANNALS OF ONCOLOGY
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
- (2018) John D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
- (2018) Rui-Hua Xu et al. LANCET ONCOLOGY
- Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer
- (2018) Stephen L. Chan et al. ONCOLOGIST
- Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials
- (2018) Takayuki Yoshino et al. Clinical Colorectal Cancer
- Folate gene prediction of treatment response to 5-FU and leucovorin in advanced colorectal cancer.
- (2018) Bengt Gustavsson et al. JOURNAL OF CLINICAL ONCOLOGY
- A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with metastatic colorectal cancer after failure of standard chemotherapy.
- (2018) Mingzhu Huang et al. JOURNAL OF CLINICAL ONCOLOGY
- 569PISO-CC-005; A phase I/II study of arfolitixorin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer
- (2018) G U Carlsson et al. ANNALS OF ONCOLOGY
- LBA18_PRDurable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
- (2018) H-J J Lenz et al. ANNALS OF ONCOLOGY
- Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis
- (2018) Alexander Baraniskin et al. EUROPEAN JOURNAL OF CANCER
- Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm
- (2017) Johannes J.M. Kwakman et al. EUROPEAN JOURNAL OF CANCER
- Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer
- (2017) Yuji Miyamoto et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach
- (2017) Michele Boisdron-Celle et al. SEMINARS IN ONCOLOGY
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action
- (2016) Peter V. Danenberg et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- ExtendedRASGene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015
- (2016) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
- (2016) D. S. Hong et al. Cancer Discovery
- Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer
- (2015) Manon Launay et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- TAS-102, a novel antitumor agent: A review of the mechanism of action
- (2015) Heinz-Josef Lenz et al. CANCER TREATMENT REVIEWS
- A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer
- (2015) Bengt Gustavsson et al. Clinical Colorectal Cancer
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
- (2015) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Unknown
- (2015) Elisabeth Odin et al. MOLECULAR MEDICINE
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort
- (2015) Halfdan Sorbye et al. PLoS One
- The predictive value ofKRAS, NRAS, BRAF, PIK3CAand PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
- (2014) Christina Therkildsen et al. ACTA ONCOLOGICA
- Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
- (2014) J. Y. Douillard et al. ANNALS OF ONCOLOGY
- A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study
- (2014) Yvonne Wettergren et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Folate levels measured by LC–MS/MS in patients with colorectal cancer treated with different leucovorin dosages
- (2014) Helena Taflin et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
- (2014) S. Venderbosch et al. CLINICAL CANCER RESEARCH
- Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
- (2014) Peter M. Wilson et al. Nature Reviews Clinical Oncology
- Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines
- (2013) D. Ransom et al. ANNALS OF ONCOLOGY
- Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed
- (2013) Antonio Avallone et al. Expert Opinion On Drug Safety
- Effect of Halogen Substitutions on dUMP to Stability of Thymidylate Synthase/dUMP/mTHF Ternary Complex Using Molecular Dynamics Simulation
- (2013) Nopporn Kaiyawet et al. Journal of Chemical Information and Modeling
- Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed by secondary metastatic resection after downsizing
- (2013) Kathrin Koucky et al. MEDICAL SCIENCE MONITOR
- Alternative Treatment Options in Colorectal Cancer Patients With 5–Fluorouracil- or Capecitabine-Induced Cardiotoxicity
- (2012) Guido Deboever et al. Clinical Colorectal Cancer
- S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial
- (2012) Yong Sang Hong et al. LANCET ONCOLOGY
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Is Levoleucovorin an Alternative to Racemic Leucovorin? A Literature Review
- (2009) Philip A. Kovoor et al. Clinical Colorectal Cancer
- Capecitabine: have we got the dose right?
- (2008) Rachel Midgley et al. Nature clinical practice. Oncology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now